Katie-May McLaughlin, Denisa Bojkova, Joshua D. Kandler, Marco Bechtel, Philipp Reus, Thi Trang Le, Florian Rothweiler, Julian Uwe Gabriel Wagner, Andreas Weigert, Sandra Ciesek, Mark N. Wass, Martin Michaelis, Jindrich Cinatl
- The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Most SARS-CoV-2 infections are mild or even asymptomatic. However, a small fraction of infected individuals develops severe, life-threatening disease, which is caused by an uncontrolled immune response resulting in hyperinflammation. However, the factors predisposing individuals to severe disease remain poorly understood. Here, we show that levels of CD47, which is known to mediate immune escape in cancer and virus-infected cells, are elevated in SARS-CoV-2-infected Caco-2 cells, Calu-3 cells, and air−liquid interface cultures of primary human bronchial epithelial cells. Moreover, SARS-CoV-2 infection increases SIRPalpha levels, the binding partner of CD47, on primary human monocytes. Systematic literature searches further indicated that known risk factors such as older age and diabetes are associated with increased CD47 levels. High CD47 levels contribute to vascular disease, vasoconstriction, and hypertension, conditions that may predispose SARS-CoV-2-infected individuals to COVID-19-related complications such as pulmonary hypertension, lung fibrosis, myocardial injury, stroke, and acute kidney injury. Hence, age-related and virus-induced CD47 expression is a candidate mechanism potentially contributing to severe COVID-19, as well as a therapeutic target, which may be addressed by antibodies and small molecules. Further research will be needed to investigate the potential involvement of CD47 and SIRPalpha in COVID-19 pathology. Our data should encourage other research groups to consider the potential relevance of the CD47/ SIRPalpha axis in their COVID-19 research.
MetadatenVerfasserangaben: | Katie-May McLaughlin, Denisa BojkovaORCiDGND, Joshua D. KandlerORCiD, Marco Bechtel, Philipp ReusORCiD, Thi Trang LeORCiD, Florian RothweilerGND, Julian Uwe Gabriel WagnerORCiDGND, Andreas WeigertORCiDGND, Sandra CiesekORCiDGND, Mark N. WassORCiD, Martin MichaelisORCiDGND, Jindrich CinatlORCiDGND |
---|
URN: | urn:nbn:de:hebis:30:3-633936 |
---|
DOI: | https://doi.org/10.3390/cimb43030086 |
---|
ISSN: | 1467-3045 |
---|
Titel des übergeordneten Werkes (Englisch): | Current issues in molecular biology |
---|
Verlag: | MDPI |
---|
Verlagsort: | Basel |
---|
Dokumentart: | Wissenschaftlicher Artikel |
---|
Sprache: | Englisch |
---|
Datum der Veröffentlichung (online): | 22.09.2021 |
---|
Datum der Erstveröffentlichung: | 22.09.2021 |
---|
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Datum der Freischaltung: | 25.01.2022 |
---|
Freies Schlagwort / Tag: | CD47; COVID-19; IAP; SARS-CoV-2; SIRPalpha; antiviral therapy; coronavirus |
---|
Jahrgang: | 43 |
---|
Ausgabe / Heft: | 3 |
---|
Seitenzahl: | 14 |
---|
Erste Seite: | 1212 |
---|
Letzte Seite: | 1225 |
---|
Bemerkung: | This research was funded by the Frankfurter Stiftung für krebskranke Kinder; the Hilfe für krebskranke Kinder Frankfurt e.V.; the Deutsche Forschungsgemeinschaft (GRK 2336); the Hessen State Ministry of Higher Education, Research, and the Arts; the BBSRC (BB/V004174/1); and the World University Service (WUS). The APC was funded by Goethe University. |
---|
HeBIS-PPN: | 491294816 |
---|
Institute: | Medizin |
---|
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Lizenz (Deutsch): | Creative Commons - Namensnennung 4.0 |
---|